Pfizer is bulking up its Mylan-Upjohn spinoff but investors may not reap rewards: analysts

Pfizer plans to sell two assets to its Mylan-Upjohn spinoff Viatris, adding $598 million in yearly revenues, but that's not doing much to raise profitability expectations, analysts warned. Problem is, Viatris is facing multiple challenges, from sales erosion in China to plummeting demand for stalwarts like Lyrica and Lipitor.